通过抑制PAD4来向非小肺癌细胞中的线粒分裂
Xiangmei Wu1,2, Liujia Chan3,4, Di Zhu4
1Department of Pathology, Beijing ChaoYang Hospital, Capital Medical University, Beijing, 150086, China.
Heliyon
|March 18, 2024
概括
丁丁氨酸减小酶4 (PAD4) 抑制抑制非小细胞肺癌 (NSCLC) 的增长,通过破坏细胞循环的进展和线粒分裂. 向PAD4为NSCLC治疗提供了一个有前途的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 在肺癌组织中,丁氨酸脱胺酶4 (PAD4) 的升高调节.
- 在肺癌患者中,PAD4的表达与淋巴结转移和膜入侵有关.
研究的目的:
- 研究PAD4在肺癌进展中的作用.
- 评估PAD4抑制在非小细胞肺癌 (NSCLC) 的治疗潜力.
主要方法:
- 用RNA测序分析PAD4抑制时的转录变化.
- 图像流细胞测量以评估细胞周期分布.
- 用小分子PAD4抑制剂 (YW3-56) 治疗肺癌细胞.
主要成果:
- 抑制PAD4诱导了亡并抑制了肺癌细胞的生长.
- 转录分析揭示了受影响的途径,包括细胞周期和p53信号传递.
- YW3-56治疗导致G1/G0阶段停止,并减少G2/M和S阶段分数.
- 线粒体分析显示,PAD4抑制后,前细胞和前细胞的增加.
结论:
- 抑制PAD4会影响肺癌细胞的细胞循环和线粒分裂.
- 向PAD4代表了对NSCLC的潜在新型治疗策略.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


